SALES

6 Months Ended

Jun. 30, 2013

Sales [Abstract]

SALES

NOTE 12 – SALES

The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. The Company’s sales by significant types of product for the three months ended June 30, 2013 and 2012 are as follows:

	For the three months ended
	June 30, 2013		June 30, 2012
	USD		USD
Human Albumin		22,764,711		19,539,419
Immunoglobulin products:
Human Immunoglobulin for Intravenous Injection		21,097,154		21,239,174
Other Immunoglobulin products		5,494,261		6,987,822
Placenta Polypeptide		3,037,991		2,509,202
Others		1,186,406		190,722
Total		53,580,523		50,466,339

The Company’s sales by significant types of product for the six months ended June 30, 2013 and 2012 are as follows:

	For the six months ended
	June 30, 2013		June 30, 2012
	USD		USD
Human Albumin		43,266,022		45,329,702
Immunoglobulin products:
Human Immunoglobulin for Intravenous Injection		46,759,025		36,500,900
Other Immunoglobulin products		10,593,986		10,773,101
Placenta Polypeptide		5,222,154		4,620,011
Others		1,771,068		470,086
Total		107,612,255		97,693,800